Navitoclax (ABT-263)

Catalog No.S1001

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Cited by 44 Publications

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )
Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Targets

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. ^[1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. ^[1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37wbWlEPTB;MD6wNFY3QSEQvF2=	NF\n[\|FUSU6JRWK=
MV-4-11	M1nxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwMEG1PFYh\|ryP	NH20fYlUSU6JRWK=
NKM-1	M1\ZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3VTWM2OD1yLkCxOlk6KM7:TR?=	MnrZV2FPT0WU
ML-2	MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnntTWM2OD1yLkCxPVg{KM7:TR?=	NEnYUWdUSU6JRWK=
BV-173	M{jtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwMEKzNVQh\|ryP	MUPTRW5ITVJ?
RS4-11	NGf4UIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPqWXk6UUN3ME2wMlAzPTh5IN88US=>	Mm\pV2FPT0WU
HL-60	NWe3S5dbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMEK5NFgh\|ryP	M3nHZnNCVkeHUh?=
KY821	M3XoVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfDO5VrUUN3ME2wMlAzQTd3IN88US=>	MUHTRW5ITVJ?
ECC10	NUXScVNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLyUHF4UUN3ME2wMlA{Pzl{IN88US=>	NHK1VnVUSU6JRWK=
NCI-H720	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwMESwNVEh\|ryP	NH72RWJUSU6JRWK=
QIMR-WIL	NYfuW2NXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4roNmlEPTB;MD6wOFI5PyEQvF2=	MkfEV2FPT0WU
KG-1	NWntXW1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4G2UmlEPTB;MD6wOFQ5PiEQvF2=	MXPTRW5ITVJ?
TGW	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMES2N\|Mh\|ryP	MkHYV2FPT0WU
ATN-1	Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwMES3N\|Mh\|ryP	NGXON3RUSU6JRWK=
RH-18	Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwME[wOFgh\|ryP	MnzwV2FPT0WU
EW-18	MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYe1bpFYUUN3ME2wMlA3QDRzIN88US=>	M33HXXNCVkeHUh?=
NB17	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVGzT\|N1UUN3ME2wMlA4OTJ2IN88US=>	MlHIV2FPT0WU
SK-NEP-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwMEeyNVMh\|ryP	NVfyPYlwW0GQR1XS
P12-ICHIKAWA	Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnyenFKSzVyPUCuNFc4PzhizszN	NVfvT2NtW0GQR1XS
KARPAS-45	NHTt[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknYTWM2OD1yLkC3PFE2KM7:TR?=	NYCxZ5NkW0GQR1XS
EW-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;pZ\|FKSzVyPUCuNFgxPTNizszN	M3[xUHNCVkeHUh?=
NB13	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMEiyNFMh\|ryP	MmPjV2FPT0WU
NCI-H209	M2jqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwMEi3NFQh\|ryP	M1rTVHNCVkeHUh?=
NCI-H1092	MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PCb2lEPTB;MD6xNFI4PSEQvF2=	MnTCV2FPT0WU
NH-12	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwMUC3OFQh\|ryP	NWPvb29PW0GQR1XS
697	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\hZZVPUUN3ME2wMlExQDN7IN88US=>	M1:xXnNCVkeHUh?=
KE-37	NFzxbphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwMUGzO{DPxE1?	NFTZ[IJUSU6JRWK=
MOLT-4	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPKTWM2OD1yLkG1NVY6KM7:TR?=	NH3YNVZUSU6JRWK=
CHP-134	NFLnVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwMU[zNFYh\|ryP	M2HxZXNCVkeHUh?=
D-283MED	Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\PZ5ZKSzVyPUCuNVc3QDZizszN	M2TncnNCVkeHUh?=
LU-135	Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fUSWlEPTB;MD6xPFU2OiEQvF2=	NHuzVJVUSU6JRWK=
LU-134-A	M3PqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwMUi2O\|Eh\|ryP	MUTTRW5ITVJ?
EM-2	M37Bdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4WwUWlEPTB;MD6xPVkyQCEQvF2=	MlTNV2FPT0WU
LU-139	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvvTWM2OD1yLkKwOFk5KM7:TR?=	NWjiV4pFW0GQR1XS
ALL-PO	MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\rTWM2OD1yLkKxPVg5KM7:TR?=	NHu3dXRUSU6JRWK=
NB12	NFP6UopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7lVHlKSzVyPUCuNlMyOTVizszN	NYrJUGt5W0GQR1XS
KP-N-YN	M3nX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPjVFZKSzVyPUCuNlM2PzNizszN	NHTYNHBUSU6JRWK=
BEN	NIjTUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml:4TWM2OD1yLkKzPVY5KM7:TR?=	M1:3THNCVkeHUh?=
HCC1569	NWq4Z4NkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7QUYFDUUN3ME2wMlI2OTB4IN88US=>	NX;lTZh7W0GQR1XS
HuO9	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHXTWM2OD1yLkK2O\|E2KM7:TR?=	NEixd5ZUSU6JRWK=
WM-115	M4LGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzSVmJKSzVyPUCuNlc4OzhizszN	MkXvV2FPT0WU
CCRF-CEM	MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwM{O1Nlkh\|ryP	MlXIV2FPT0WU
IST-SL1	MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfXc3JKSzVyPUCuN\|U{PDNizszN	M3H1OXNCVkeHUh?=
BE-13	M1TVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\ncYJKSzVyPUCuN\|Y1PTlizszN	NFHnWpRUSU6JRWK=
COR-L88	NHzITpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwM{[1OEDPxE1?	M1LKVXNCVkeHUh?=
DOHH-2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{G1SGlEPTB;MD60NVAzOyEQvF2=	M1uyS3NCVkeHUh?=
A704	NUHuTJB2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4e0NmlEPTB;MD60NlY4KM7:TR?=	M2Xi[XNCVkeHUh?=
KNS-81-FD	NH3y[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwNESwNVch\|ryP	Moj2V2FPT0WU
RPMI-8226	M4r1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwNEW2OVIh\|ryP	NV7oWnJNW0GQR1XS
TGBC24TKB	NFPsRWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXrTWM2OD1yLkS1O\|c5KM7:TR?=	MVXTRW5ITVJ?
NCI-H1304	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjNS4xKSzVyPUCuOFYyPTdizszN	MVrTRW5ITVJ?
MOLT-13	M13KcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwNE[2NVMh\|ryP	Mn7mV2FPT0WU
EW-22	MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rrUGlEPTB;MD60OlY4OSEQvF2=	NXnKblFXW0GQR1XS
MS-1	NInWO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHrTWM2OD1yLkS2PVM{KM7:TR?=	NFrIRldUSU6JRWK=
RMG-I	MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jIdWlEPTB;MD60PVQ3PCEQvF2=	NED1OVVUSU6JRWK=
NTERA-S-cl-D1	NHXRTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LnTWlEPTB;MD61NFAyQSEQvF2=	MUDTRW5ITVJ?
NCI-H1048	Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvoSFdKSzVyPUCuOVA6PTNizszN	NGrG[JlUSU6JRWK=
SW1417	NXjae4lwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2D2N2lEPTB;MD61OVQ{QCEQvF2=	NELIPHJUSU6JRWK=
DB	M4rJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3OWJdSUUN3ME2wMlU4ODhizszN	NGfBXW1USU6JRWK=
MEG-01	M1K0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXUbG5KSzVyPUCuOVg{OiEQvF2=	MlS2V2FPT0WU
EW-13	NV7aNnZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwNUizOFEh\|ryP	MWHTRW5ITVJ?
LAMA-84	M4XUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\ZVGlEPTB;MD61PVIxPyEQvF2=	NV:3V\|ZrW0GQR1XS
J-RT3-T3-5	M13WNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIK3c4JKSzVyPUCuOlA5ODhizszN	MWLTRW5ITVJ?
MOLT-16	Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwNkWyOlQh\|ryP	MYfTRW5ITVJ?
DU-4475	M4mzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmj0TWM2OD1yLk[1OFI4KM7:TR?=	MXzTRW5ITVJ?
HAL-01	NH\BSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\DeXpKSzVyPUCuO\|I2PDlizszN	NIXk[FVUSU6JRWK=
RD	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fK[mlEPTB;MD63OVg6QSEQvF2=	NGnnbZZUSU6JRWK=
OAW-28	NWrWT40yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDKTWM2OD1yLke4N\|ch\|ryP	MknJV2FPT0WU
HCC38	NGGwUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETiPXNKSzVyPUCuPFAyQSEQvF2=	M{\jVXNCVkeHUh?=
NMC-G1	NG\VfXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7ZTWM2OD1yLkixNVIyKM7:TR?=	NV\5XldMW0GQR1XS
EW-16	NU\tV4t3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHpTVVKSzVyPUCuPFE{OjhizszN	NVLJOHdxW0GQR1XS
DU-145	NWC2TJVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4D4bWlEPTB;MD64PVkzOyEQvF2=	NHzyPGJUSU6JRWK=
HPAF-II	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4f4NmlEPTB;MD65NlYzQCEQvF2=	M3\WO3NCVkeHUh?=
A427	NIPqXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfjSJhmUUN3ME2wMlk{ODJ{IN88US=>	NH3EcXZUSU6JRWK=
PA-1	NFPGZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDhVpZKSzVyPUCuPVU3PDJizszN	MnixV2FPT0WU
OAW-42	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PpOGlEPTB;MD65OlE1PiEQvF2=	MlnQV2FPT0WU
L-428	NILqSGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIKyRlZKSzVyPUGuNFEzPSEQvF2=	MWnTRW5ITVJ?
COLO-824	M3ntc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVO2cmtqUUN3ME2xMlAyPzB6IN88US=>	M17LV3NCVkeHUh?=
P30-OHK	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nWbmlEPTB;MT6wOFY5QCEQvF2=	M1W2RnNCVkeHUh?=
NCI-H2170	MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHGycHhKSzVyPUGuNFYzOyEQvF2=	NX6z[I0yW0GQR1XS
HCC2998	M{LSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVKzc\|FtUUN3ME2xMlA4OTN3IN88US=>	NF33PI5USU6JRWK=
NB14	NGXKeHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTFwMUO3OFgh\|ryP	MV;TRW5ITVJ?
TGBC1TKB	NGDFeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETNOnVKSzVyPUGuNVQyPTJizszN	MXHTRW5ITVJ?
KP-N-YS	MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHoTWM2OD1zLkG2NlM3KM7:TR?=	NYjBVXd6W0GQR1XS
CAL-120	M2T6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTOTWM2OD1zLkG2OFI6KM7:TR?=	M2\FVXNCVkeHUh?=
SBC-1	M4XDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfyVXJKSzVyPUGuNVkxPTNizszN	MYPTRW5ITVJ?
C32	MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfGPGdTUUN3ME2xMlE6ODh6IN88US=>	NF\IdGZUSU6JRWK=
HCC2157	M4fPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HoW2lEPTB;MT6xPVQ6PCEQvF2=	M{HtdXNCVkeHUh?=
COLO-792	M1fZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTFwMkCwO\|Eh\|ryP	M1K3ZnNCVkeHUh?=
ES7	NFGzUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrtW\|RKSzVyPUGuNlc6PTFizszN	NEnN[2VUSU6JRWK=
HEL	NUDBe4xMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTFwM{GwNlkh\|ryP	MmTtV2FPT0WU
ES4	M4nwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH70SXNKSzVyPUGuN\|Q6QThizszN	NIrDZlVUSU6JRWK=
NCI-SNU-1	Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXpXFFKSzVyPUGuN\|Y2PTVizszN	NITSPXRUSU6JRWK=
MDA-MB-415	NYnBVZdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTFwM{i4OUDPxE1?	NUnxOolrW0GQR1XS
NCI-H2342	M2W0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TEcmlEPTB;MT60NFI3QSEQvF2=	NYrDOVBqW0GQR1XS
NB69	NHnNOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFy4ToNKSzVyPUGuOFYzPzFizszN	NEnRT2VUSU6JRWK=
D-247MG	NXrBZ\|M3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzYTWM2OD1zLkWxNVIzKM7:TR?=	NVq0ZXhZW0GQR1XS
SCC-4	NHWzclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHWXW1KSzVyPUGuOVk5QDdizszN	NHT2fJZUSU6JRWK=
HuH-7	Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEe0TXJKSzVyPUGuOlczQTNizszN	MWPTRW5ITVJ?
A388	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrwcHRKSzVyPUGuOlg4OjRizszN	MXnTRW5ITVJ?
Calu-3	M2D4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PtO2lEPTB;MT63NFY6PyEQvF2=	M3fIeXNCVkeHUh?=
NCI-H1648	NUHhO4Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjXTpJ{UUN3ME2xMlcyPDF6IN88US=>	M2TGXXNCVkeHUh?=
NCI-H2052	MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\XTWM2OD1zLkeyNlAyKM7:TR?=	NWHqd\|BnW0GQR1XS
Ramos-2G6-4C10	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTFwN{O2OVYh\|ryP	MYLTRW5ITVJ?
DEL	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfpTWM2OD1zLke0OlkzKM7:TR?=	NUXIfJloW0GQR1XS
SNU-423	Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4eyOWlEPTB;MT63PFE2PyEQvF2=	NIqzZnNUSU6JRWK=
COR-L23	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHjTWM2OD1zLke5PFc1KM7:TR?=	M2KyRXNCVkeHUh?=
OMC-1	M3TmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\KRYd{UUN3ME2xMlg3ODF4IN88US=>	MknDV2FPT0WU
EW-11	NXH4UGZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1K3dmlEPTB;MT65OVY2PyEQvF2=	NXjWZ4J2W0GQR1XS
HSC-3	M1zYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTFwOU[zOlUh\|ryP	NHLofGpUSU6JRWK=
MLMA	M3TKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTFwOU[2O\|ch\|ryP	MVXTRW5ITVJ?
RCM-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PLWGlEPTB;Mj6wNFM6QSEQvF2=	NXnScGRFW0GQR1XS
MFE-280	M4\zWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnuWlZKSzVyPUKuNFI5PDhizszN	NXz1cJEyW0GQR1XS
ES8	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2j3OGlEPTB;Mj6yOVQ4OSEQvF2=	MlvKV2FPT0WU
TE-11	M3Hmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TxcGlEPTB;Mj6yPVQ4OyEQvF2=	NFfhdnNUSU6JRWK=
HuO-3N1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4G3S2lEPTB;Mj60PFc5KM7:TR?=	NUHTOVltW0GQR1XS
MHH-NB-11	MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXGbXZqUUN3ME2yMlUyOTV6IN88US=>	M3zSfXNCVkeHUh?=
TGBC11TKB	NF\IOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTJwNUe2PFEh\|ryP	M{fidXNCVkeHUh?=
HOP-92	NIDXR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfPTItKSzVyPUKuOVg4PDNizszN	MmHkV2FPT0WU
IGR-1	NXn4[md1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrSfVVGUUN3ME2yMlYzODN3IN88US=>	MYfTRW5ITVJ?
GOTO	Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XsV2lEPTB;Mj62OVM4PyEQvF2=	NHf5V4NUSU6JRWK=
NCI-H1650	NHS1ZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjvTWM2OD1{LkeyNlE2KM7:TR?=	M4\Lb3NCVkeHUh?=
NCI-H1581	NV7ZXZBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\RTWM2OD1{Lke5OlgyKM7:TR?=	NG\xflJUSU6JRWK=
NCI-H2405	Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLo[3BKSzVyPUKuPFI4QDJizszN	Mo\xV2FPT0WU
U-118-MG	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HqZ2lEPTB;Mj65OlQ6OSEQvF2=	M3vJc3NCVkeHUh?=
DoTc2-4510	NGDYVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml33TWM2OD1\|LkCxOFE4KM7:TR?=	MXHTRW5ITVJ?
NCI-H596	MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFz5eGhKSzVyPUOuNFQ6QTdizszN	NFPzXGJUSU6JRWK=
MPP-89	M1Hpc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTNwMEW2OlYh\|ryP	MlvlV2FPT0WU
GCIY	M4\ldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEf5PYdKSzVyPUOuNlA1QTFizszN	NFTCNVJUSU6JRWK=
SW626	NYXNRlQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTNwMkS1OFMh\|ryP	NV7SOWxmW0GQR1XS
OCI-AML2	NXHJNXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTNwM{GyO\|Ih\|ryP	NIHtV\|ZUSU6JRWK=
NBsusSR	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\qd3ZWUUN3ME2zMlM1QTN6IN88US=>	NIfmTllUSU6JRWK=
AN3-CA	MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUH4VWxkUUN3ME2zMlQ1OjN6IN88US=>	NWPD[YtOW0GQR1XS
EFM-19	NUXPeGk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfsXnpKSzVyPUOuOFg{OzlizszN	MY\TRW5ITVJ?
RVH-421	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\xU3lKSzVyPUOuOVY5PzdizszN	Mm\YV2FPT0WU
5637	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TmeWlEPTB;Mz62NVExOyEQvF2=	Ml75V2FPT0WU
PANC-08-13	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jNW2lEPTB;Mz62N\|Q4OiEQvF2=	NY\RUJFEW0GQR1XS
H9	M3fGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTNwNkexOFQh\|ryP	NUD3V4NCW0GQR1XS
KARPAS-299	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU[wbplHUUN3ME2zMlY4OzZzIN88US=>	NF;BTWNUSU6JRWK=
TE-5	M4LheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDB[\|VuUUN3ME2zMlcxPzB7IN88US=>	MoTPV2FPT0WU
NOS-1	NHPQSGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PkNGlEPTB;Mz63PVg{PCEQvF2=	NULDZZBWW0GQR1XS
HH	NHrGOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTNwOEO4Olgh\|ryP	MUDTRW5ITVJ?
769-P	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELzNItKSzVyPUOuPFk2OSEQvF2=	M2qxRnNCVkeHUh?=
CHP-212	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HH[mlEPTB;Mz65NlU1QSEQvF2=	Mn3SV2FPT0WU
NCI-H82	M1PWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{[0NmlEPTB;Mz65OVk{PiEQvF2=	MXzTRW5ITVJ?
Mo-T	NF;OUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV73Nmg4UUN3ME20MlA1OzF{IN88US=>	Mnf5V2FPT0WU
BB65-RCC	MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfzZ4RKSzVyPUSuNFQ{QTlizszN	NY[zV3pLW0GQR1XS
SW1990	NFHG[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm[1TWM2OD12LkC1PVA5KM7:TR?=	NEfEbFdUSU6JRWK=
LK-2	M3:5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTRwMUGyPVMh\|ryP	MlPsV2FPT0WU
ES5	NFXrSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPu[HpzUUN3ME20MlE{QTh3IN88US=>	M4XBTXNCVkeHUh?=
JVM-3	NEfhV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3myeWlEPTB;ND6xPFIzOiEQvF2=	NHz0RlFUSU6JRWK=
RPMI-7951	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTQTWM2OD12LkKyOFE{KM7:TR?=	MWDTRW5ITVJ?
Calu-6	NES3c4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TuUWlEPTB;ND6yO\|g5OSEQvF2=	NHzxUpNUSU6JRWK=
LC-2-ad	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfYTWM2OD12LkK5OVY5KM7:TR?=	NHfsXpVUSU6JRWK=
SW954	M4P6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1W1fWlEPTB;ND6yPVY3KM7:TR?=	M3PxUXNCVkeHUh?=
H-EMC-SS	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnHTWM2OD12LkOxPFMyKM7:TR?=	M3H6NnNCVkeHUh?=
ES3	NGfONHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTRwM{W0OFEh\|ryP	MU\TRW5ITVJ?
no-11	MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDVNpZRUUN3ME20MlM2PTV2IN88US=>	MWnTRW5ITVJ?
LAN-6	M4rNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vr[WlEPTB;ND60OVE5QSEQvF2=	MX;TRW5ITVJ?
FTC-133	MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTRwNUO5OUDPxE1?	MX\TRW5ITVJ?
8505C	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfBVXRlUUN3ME20MlU1OjNizszN	M{XzdHNCVkeHUh?=
SW620	M3LJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTRwNUewOVch\|ryP	MYTTRW5ITVJ?
BCPAP	NWO3NYxyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvCTWM2OD12Lk[zOFgyKM7:TR?=	NUPq[IlTW0GQR1XS
SK-LU-1	NWPHcoJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7FfWR2UUN3ME20MlY3ODh7IN88US=>	M1TIbnNCVkeHUh?=
NCI-H1623	M2jjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Tpd2lEPTB;ND63NFIzQCEQvF2=	NEPBXnRUSU6JRWK=
C2BBe1	NH2ySZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXDTWM2OD12Lke0NFA5KM7:TR?=	MnGyV2FPT0WU
GP5d	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTRwN{izPFgh\|ryP	M{jvbXNCVkeHUh?=
NB6	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTRwOE[yNFQh\|ryP	Ml7QV2FPT0WU
MDA-MB-157	NWfWTGhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmqyTWM2OD12Lki4O\|Yh\|ryP	NYPVPYtYW0GQR1XS
UMC-11	M4LmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTRwOEi5OlQh\|ryP	MmLkV2FPT0WU
HCC1419	M1X5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVf5Sop6UUN3ME20MlkxODZ\|IN88US=>	MWPTRW5ITVJ?
NCI-H2029	NYrnUm4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH6yfIpKSzVyPUSuPVQyQDVizszN	MYfTRW5ITVJ?
LXF-289	M{jaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF33d4hKSzVyPUWuNFM4OTlizszN	Mn\rV2FPT0WU
KINGS-1	NVrzPVNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHNTWM2OD13LkC3O\|Q1KM7:TR?=	NFK1VW1USU6JRWK=
HD-MY-Z	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PmbWlEPTB;NT6yN\|k3QSEQvF2=	NVfrbHM1W0GQR1XS
ESS-1	NEDnfY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILRU4pKSzVyPUWuNlU2QTdizszN	M2\4d3NCVkeHUh?=
GI-1	M4LmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nSUWlEPTB;NT6yO\|kzPiEQvF2=	MlfHV2FPT0WU
RPMI-2650	M1u0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;jZWlEPTB;NT6zOlE3KM7:TR?=	M4raR3NCVkeHUh?=
IA-LM	Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLpTWM2OD13LkO5PFcyKM7:TR?=	NXTWPHdvW0GQR1XS
KP-4	NGDOcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonOTWM2OD13LkS2N\|M1KM7:TR?=	M{mxbXNCVkeHUh?=
G-402	NVfQbXFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TGSGlEPTB;NT61NVg3PSEQvF2=	NHLOfYdUSU6JRWK=
OS-RC-2	MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnW4TWM2OD13LkWyOlA1KM7:TR?=	MVXTRW5ITVJ?
NCI-H1155	MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vIV2lEPTB;NT61OFk2PSEQvF2=	NX\l[WM5W0GQR1XS
OE19	M{C3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjmUVlxUUN3ME21MlY5PjJ2IN88US=>	M1eyeXNCVkeHUh?=
U-2-OS	MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjZTWM2OD13Lki5NFE{KM7:TR?=	MoS5V2FPT0WU
SCC-15	NVfmbFV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX20TJl2UUN3ME21Mlk{PjZ{IN88US=>	NHLBR3lUSU6JRWK=
NCI-H630	M2PHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTVwOUm0NFQh\|ryP	MUjTRW5ITVJ?
PFSK-1	M2eyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTZwMEWyOVkh\|ryP	NFvHSY1USU6JRWK=
NCI-H1770	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk[wTWM2OD14LkKwPFc1KM7:TR?=	M3POS3NCVkeHUh?=
SK-MEL-3	M1rP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTZwNEK5NVUh\|ryP	M3HwfHNCVkeHUh?=
LB1047-RCC	NX;wSIo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXvWXBKSzVyPU[uOFc3OjVizszN	NWHKTVZGW0GQR1XS
NCI-H446	MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTZwNkK5NlUh\|ryP	NETVNY9USU6JRWK=
SW780	MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\GPGlEPTB;Nj63NFE5PSEQvF2=	MX\TRW5ITVJ?
NEC8	Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTZwN{[2N{DPxE1?	MX3TRW5ITVJ?
NOMO-1	M2S1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrjS3MyUUN3ME22Mlc5OTFzIN88US=>	NV7zc3NMW0GQR1XS
COLO-668	MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTZwOESzPFch\|ryP	NVi0OGdCW0GQR1XS
MC116	NF[3fY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWizRm9lUUN3ME22Mlk{QDl5IN88US=>	M4\BXXNCVkeHUh?=
HCC1937	NES4PIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\pNIRKSzVyPU[uPVkzPTFizszN	NH\aXmhUSU6JRWK=
NCI-N87	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTHTWM2OD15LkG5Nlk{KM7:TR?=	M4L2bXNCVkeHUh?=
COLO-320-HSR	MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnLemRDUUN3ME23MlIzPzN6IN88US=>	M4jJUnNCVkeHUh?=
HCC1806	M2H6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfiNWdEUUN3ME23MlI3ODR2IN88US=>	Mn3oV2FPT0WU
OVCAR-3	NFKwTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{D5OWlEPTB;Nz6zN\|A{QCEQvF2=	MV;TRW5ITVJ?
NUGC-3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXX6SotYUUN3ME23MlM6Pjl2IN88US=>	MY\TRW5ITVJ?
SW1783	M2POZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTdwNEOxO\|Uh\|ryP	MXfTRW5ITVJ?
GCT	Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvKb41KSzVyPUeuOVY6ODZizszN	MlS4V2FPT0WU
NCI-H2126	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zUTGlEPTB;Nz63N\|YzPSEQvF2=	NF7RTGpUSU6JRWK=
MEL-HO	Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTdwN{ewOVQh\|ryP	M4LjOHNCVkeHUh?=
CAPAN-1	NX3GToU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2P5N2lEPTB;Nz63O\|M2PyEQvF2=	MYjTRW5ITVJ?
SW756	NHnRdW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUSyPHZnUUN3ME23Mlc5OzN\|IN88US=>	Mk\QV2FPT0WU
SKG-IIIa	MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFS3XIFKSzVyPUeuPFE5QTJizszN	M3zXOXNCVkeHUh?=
HCE-T	NX;Bd29FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XJfWlEPTB;Nz64O\|c5OyEQvF2=	NEnRRoFUSU6JRWK=
Ca-Ski	MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTdwOUmzPFMh\|ryP	MVfTRW5ITVJ?
COLO-684	NYizcpllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjhZpJJUUN3ME24MlAyQDF6IN88US=>	NEewTpFUSU6JRWK=
KYSE-70	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LicGlEPTB;OD6wO\|czQSEQvF2=	MX3TRW5ITVJ?
TI-73	Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTrTWM2OD16LkK1PFUyKM7:TR?=	NH;zb\|lUSU6JRWK=
BT-20	MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHu4OZBKSzVyPUiuNlYxPTJizszN	NFTmZppUSU6JRWK=
MHH-ES-1	MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEOxcnBKSzVyPUiuOVE5OzRizszN	NI\tPY1USU6JRWK=
TE-12	NETtSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrkd4pKSzVyPUiuOVk6OzFizszN	NUjUXHlbW0GQR1XS
YH-13	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrUZYY5UUN3ME24MlYyODB6IN88US=>	MlPTV2FPT0WU
SF126	MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLJWYV{UUN3ME24Mlg{QDZ3IN88US=>	MlmwV2FPT0WU
J82	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRThwOUCwN\|gh\|ryP	NED5RWVUSU6JRWK=
RCC10RGB	NGHle4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1P2XGlEPTB;OD65PVU3OSEQvF2=	M4\wRnNCVkeHUh?=
SK-UT-1	NGP4[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTlwMES5OFUh\|ryP	NF2weI9USU6JRWK=
LB2241-RCC	NX:yeJNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTlwMUmxN\|ch\|ryP	MXvTRW5ITVJ?
LB996-RCC	MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;CVYhOUUN3ME25MlE6QDlizszN	MUjTRW5ITVJ?
EPLC-272H	M4TI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn6xTWM2OD17LkO3OlU4KM7:TR?=	NEDUVYhUSU6JRWK=
CTV-1	MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jKNmlEPTB;OT61OlU{OiEQvF2=	MVfTRW5ITVJ?
HSC-2	NV:1Z5FiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPxTWM2OD17LkW3OVUh\|ryP	MVfTRW5ITVJ?
SK-MEL-28	M1Xabmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DadGlEPTB;OT62NVg6OyEQvF2=	MmDhV2FPT0WU
MMAC-SF	NIHpUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3OTWM2OD17Lk[4O\|Uh\|ryP	NFvRV4NUSU6JRWK=
CP50-MEL-B	NY[1doRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TyfWlEPTB;OT63OVc5OiEQvF2=	NWP1V3oyW0GQR1XS
HT-1080	NFHNNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nSNmlEPTB;OT63O\|c{QSEQvF2=	NFT5[4tUSU6JRWK=
HEC-1	MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfSTodKSzVyPUGwMlM{PTJizszN	MXrTRW5ITVJ?
AGS	MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXwNXpKSzVyPUGwMlM4PCEQvF2=	MXzTRW5ITVJ?
GAMG	NV3GRXg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPGTWM2OD1zMD61NVYzKM7:TR?=	M4rvUnNCVkeHUh?=
SW48	NFe4VlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDlSIpKSzVyPUGwMlUyQDlizszN	Mn3nV2FPT0WU
U031	NFrIcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PvU2lEPTB;MUCuOVkxQCEQvF2=	MmO1V2FPT0WU
OVCAR-5	Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;5bGlEPTB;MUCuOlQzQSEQvF2=	MWLTRW5ITVJ?
SF295	NVf6N29ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTaTWM2OD1zMD62O\|A1KM7:TR?=	MoHqV2FPT0WU
BHT-101	MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjNUnhVUUN3ME2xNE44OTd5IN88US=>	MYTTRW5ITVJ?
VMRC-RCZ	NYXKb3k5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTFzLkOyNFEh\|ryP	M3LZ[XNCVkeHUh?=
ACHN	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nWcWlEPTB;MUGuOFIyOSEQvF2=	NIrPZWFUSU6JRWK=
NCI-H526	NX[4SZpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTFzLkWwOFMh\|ryP	M3HPbnNCVkeHUh?=
MN-60	NFPzeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVO4dJREUUN3ME2xNU42OzlizszN	M2LjeXNCVkeHUh?=
NCI-H2291	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;hWWlEPTB;MUGuOVQ3PiEQvF2=	M1;DSnNCVkeHUh?=
SCC-25	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDOTWM2OD1zMT63OVU3KM7:TR?=	MkS2V2FPT0WU
SK-MEL-2	M4PQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTFzLke2N\|ch\|ryP	MmThV2FPT0WU
SN12C	NVL6blc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojQTWM2OD1zMT65N\|U2KM7:TR?=	MoX3V2FPT0WU
NCI-H69	NYXER2k6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrsUpNKSzVyPUGyMlQzOzRizszN	NILrR5lUSU6JRWK=
ME-180	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTF{LkewOVQh\|ryP	NYft[lNMW0GQR1XS
MC-IXC	M{nUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTF{Lke1NVgh\|ryP	M{XUNnNCVkeHUh?=
NCI-H2347	Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzH[\|ZGUUN3ME2xNk44PjF2IN88US=>	M2nxXnNCVkeHUh?=
M059J	M4PVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLJV5ExUUN3ME2xNk44PzJ5IN88US=>	MVvTRW5ITVJ?
A2058	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvaTWM2OD1zMj64OlgyKM7:TR?=	MonRV2FPT0WU
VA-ES-BJ	NXvE[ox7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTF{Lki3PFUh\|ryP	MnLmV2FPT0WU
Ca9-22	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7NfFBKSzVyPUGyMlk1PTFizszN	MV7TRW5ITVJ?
KNS-42	NY\YdHZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvrTWM2OD1zMj65PVg1KM7:TR?=	MY\TRW5ITVJ?
LoVo	Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3Trb2lEPTB;MUOuNlMyOyEQvF2=	MWLTRW5ITVJ?
AM-38	NWrJO2lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\0O25mUUN3ME2xN{4zPTZ4IN88US=>	MXLTRW5ITVJ?
NB5	NE\FVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXrVoZKSzVyPUGzMlM4PTJizszN	Mnm3V2FPT0WU
L-363	MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHYcZdKSzVyPUGzMlQxOzNizszN	M17ZeXNCVkeHUh?=
SK-MEL-30	NGLLflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnkTWM2OD1zND6wOlQ2KM7:TR?=	NHHid49USU6JRWK=
NCI-H1563	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTF2Lk[wN\|kh\|ryP	NUfROldNW0GQR1XS
NCI-H2228	M2PUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvDTIZKSzVyPUG0MlYxPzdizszN	M1nCU3NCVkeHUh?=
MFM-223	MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTF3LkG4NVMh\|ryP	NG\CRphUSU6JRWK=
LB831-BLC	NVHXXmZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLWVmtKSzVyPUG1MlI4PjdizszN	NX3ScpdxW0GQR1XS
SW872	MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXDTWM2OD1zNT6zNFg3KM7:TR?=	MWXTRW5ITVJ?
NCI-H522	M4j0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTF3LkOzNFYh\|ryP	Mn7IV2FPT0WU
EW-1	NFXmZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGq0OnJKSzVyPUG1MlU1PjJizszN	NFzDbHVUSU6JRWK=
HN	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFu3dm1KSzVyPUG1MlU6PDJizszN	MnizV2FPT0WU
SW837	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTF3Lke4OFch\|ryP	Mlf6V2FPT0WU
SCC-9	NWDHZXl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLDTWM2OD1zNT64NVE1KM7:TR?=	MmnoV2FPT0WU
MKN7	M2HlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTVVnpKSzVyPUG1Mlk4OzJizszN	NVewR5NkW0GQR1XS
KYSE-410	NVrUdZJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknHTWM2OD1zNj61PVEh\|ryP	M2LGTXNCVkeHUh?=
SK-N-DZ	NGL4VJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTF4Lk[xNVYh\|ryP	NX:1cYwyW0GQR1XS
COR-L105	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2P2cGlEPTB;MU[uOlUzQCEQvF2=	NFr2OWZUSU6JRWK=
LB2518-MEL	NULV[oF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzKZpdKSzVyPUG2Mlg{QDlizszN	MX3TRW5ITVJ?
OVCAR-4	M1HzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTF4Lki4OlIh\|ryP	MYTTRW5ITVJ?
TK10	M1\seGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TZSGlEPTB;MU[uPVQ4OyEQvF2=	NE\RVGNUSU6JRWK=
KNS-62	NIL1eFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTF4Lkm3O\|ch\|ryP	NVrXWZV[W0GQR1XS
RPMI-8866	NYXyOYFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo[wTWM2OD1zNz6xO\|MzKM7:TR?=	Ml;YV2FPT0WU
HuP-T4	NEjZbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\3bWNKSzVyPUG3MlI1QTVizszN	M3LRdXNCVkeHUh?=
CGTH-W-1	M3nqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrWWFBCUUN3ME2xO{42OjF7IN88US=>	NEXSeotUSU6JRWK=
T-24	NVPKOmJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;JfmNKSzVyPUG3MlU{PDdizszN	MX;TRW5ITVJ?
HT-3	NGi2TINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH2xZYdKSzVyPUG3MlU6OTRizszN	M{Hte3NCVkeHUh?=
KS-1	NYi4WZZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTF5Lk[3N{DPxE1?	M1rqOXNCVkeHUh?=
NCI-H1792	NETafWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTF5Lke5PEDPxE1?	NX3xdVROW0GQR1XS
ABC-1	MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTMfpZtUUN3ME2xO{45OTRzIN88US=>	NGTRV\|ZUSU6JRWK=
BPH-1	NVXPT5VzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTF6LkG2PFUh\|ryP	MmnoV2FPT0WU
A431	M{nTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjYWJlOUUN3ME2xPE41OTJ5IN88US=>	Ml3vV2FPT0WU
T98G	NVfOeVM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTF6LkWxOVch\|ryP	MUjTRW5ITVJ?
BHY	MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLKPG1TUUN3ME2xPE45PjlizszN	NIXTN4tUSU6JRWK=
Capan-2	NWrxbm1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDETWM2OD1zOD65NFc5KM7:TR?=	MUfTRW5ITVJ?
MDA-MB-175-VII	NU\SbmkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTF6LkmyNFkh\|ryP	MWnTRW5ITVJ?
CAL-27	NX7wNFY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\zO41OUUN3ME2xPU4xPDh5IN88US=>	M3ryd3NCVkeHUh?=
AsPC-1	Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrwTWM2OD1zOT64OlU4KM7:TR?=	NX\4OI9RW0GQR1XS
KU812	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi5elRKSzVyPUG5Mlk2PzNizszN	M2n0WXNCVkeHUh?=
NCI-H441	MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTJyLkCwNUDPxE1?	Mli2V2FPT0WU
Mewo	NHj4N4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7WOVRKSzVyPUKwMlEzQDhizszN	NVvmZoh4W0GQR1XS
SK-MEL-24	NILBWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjvT3lsUUN3ME2yNE4yPDd5IN88US=>	MYjTRW5ITVJ?
NCI-H727	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXY[WxKSzVyPUKwMlI4ODRizszN	MX;TRW5ITVJ?
EKVX	NIDwSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7QTWM2OD1{MD62NFYh\|ryP	NXnYTnY4W0GQR1XS
RT-112	NIXaPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\OZ445UUN3ME2yNE43OTJ{IN88US=>	NVzBcmdvW0GQR1XS
CAMA-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH:0XFNKSzVyPUKwMlk5ODNizszN	NXHleI5iW0GQR1XS
SW900	NVzzWJB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrmPJJEUUN3ME2yNU4xOTR7IN88US=>	MmLmV2FPT0WU
NCI-H23	NFXqV\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTmTWM2OD1{MT6xNlc4KM7:TR?=	Mn7SV2FPT0WU
SK-PN-DW	NGLhSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTJzLkG2OFkh\|ryP	M{nBOnNCVkeHUh?=
BB30-HNC	NHryZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLvTWM2OD1{MT6yO\|Q2KM7:TR?=	MUDTRW5ITVJ?
VM-CUB-1	M1nhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFOwOm1KSzVyPUKxMlM2OzZizszN	NYjDcVd7W0GQR1XS
IST-MEL1	NX\tepZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPlfos2UUN3ME2yNU4{Pjl{IN88US=>	NUnTR2wyW0GQR1XS
CTB-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvCR4Z3UUN3ME2yNU41PzV3IN88US=>	MUDTRW5ITVJ?
LCLC-103H	NXjUd5lTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXEemt6UUN3ME2yNk4yPTh{IN88US=>	MmjrV2FPT0WU
PANC-03-27	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTJ{LkWxOlkh\|ryP	NULlbZplW0GQR1XS
HTC-C3	NV3RXY57T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTJ{LkW1OVUh\|ryP	MnrWV2FPT0WU
TE-8	MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLlSYJzUUN3ME2yN{4zPTZ3IN88US=>	M4e0NXNCVkeHUh?=
NCI-H292	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Pje2lEPTB;MkWuN\|U{PiEQvF2=	NYP3U3RkW0GQR1XS
COLO-680N	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPrO3d2UUN3ME2yOU43OzJ7IN88US=>	NWe2eWIyW0GQR1XS
KYSE-520	M2m1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHYTWM2OD1{NT62OFQh\|ryP	MnTjV2FPT0WU
NB10	MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfYT496UUN3ME2yOk4{OTF5IN88US=>	MoDGV2FPT0WU
NCI-H661	MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTJ4LkS3NVMh\|ryP	MWHTRW5ITVJ?
GMS-10	NFjycWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETIbWtKSzVyPUK2Mlg3OzhizszN	NV3TS2l6W0GQR1XS
NCI-H2122	Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPNTWM2OD1{Nj65PVk5KM7:TR?=	MULTRW5ITVJ?
OVCAR-8	NUXtR3pHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rydWlEPTB;MkeuNFY{QCEQvF2=	NHLjb4xUSU6JRWK=
DJM-1	MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\CWGlEPTB;MkeuNVQ2PCEQvF2=	MXrTRW5ITVJ?
UACC-893	NVLJW5RGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTJ5Lkm4O\|gh\|ryP	NWXtd3YyW0GQR1XS
C8166	M{LC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vtfWlEPTB;MkiuOlk{QCEQvF2=	NVPvV3diW0GQR1XS
NCI-H1693	NIHQN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLUb5FKSzVyPUK4MlY6PzVizszN	M1jqc3NCVkeHUh?=
TYK-nu	NGn0fnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjoTWM2OD1\|MD6wN\|Q2KM7:TR?=	NIq4U25USU6JRWK=
SW1710	Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3abZpKSzVyPUOwMlEzPiEQvF2=	M2K0VXNCVkeHUh?=
A375	NF:1c29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\vO4xKSzVyPUOwMlMzPDNizszN	NUHqd4poW0GQR1XS
HMV-II	MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7vN5NGUUN3ME2zNU4{PTl{IN88US=>	MmD6V2FPT0WU
NCI-H2087	M1fuRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLKTWJzUUN3ME2zNU43OzV{IN88US=>	NXzLV\|d3W0GQR1XS
CAL-54	MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXnTWM2OD1\|MT63NlQyKM7:TR?=	MUfTRW5ITVJ?
HCC70	NUPlT\|lqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DaNWlEPTB;M{KuNVM5PyEQvF2=	MkDUV2FPT0WU
ES1	M2L2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\YcotKSzVyPUOyMlMxPjJizszN	MoH6V2FPT0WU
NCI-H1355	M4O1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfWTlFKSzVyPUOzMlIxPCEQvF2=	NYe2ZVdZW0GQR1XS
CFPAC-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTN\|LkKzN\|Ih\|ryP	M4rlWHNCVkeHUh?=
MKN28	NV;PbIpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NES0S45KSzVyPUOzMlM5ODlizszN	NYjsb5J7W0GQR1XS
HDLM-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7lcYRKSzVyPUOzMlY6OzFizszN	NIqycFZUSU6JRWK=
PANC-10-05	NFjteIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nRRmlEPTB;M{SuNVAyPCEQvF2=	NH7kWopUSU6JRWK=
SAS	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTN2LkS1OlUh\|ryP	NXW0b5AyW0GQR1XS
HCC1395	M{PwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITKbYRKSzVyPUO0MlcyQDZizszN	NGLLfVBUSU6JRWK=
8305C	MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3mTWM2OD1\|NT64OFE2KM7:TR?=	Mm[zV2FPT0WU
KM12	NYDsPZZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHn4PI1KSzVyPUO2Mlc2PDdizszN	NHHMU\|NUSU6JRWK=
SW1116	NGXINVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTwV2RKSzVyPUO3MlU6QTJizszN	M1\4d3NCVkeHUh?=
SK-MEL-1	MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHwTWM2OD1\|OD6zN\|g6KM7:TR?=	NYXqTVE6W0GQR1XS
HCC2218	NXnyXGdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnBRZVKSzVyPUO4MlY2OTlizszN	MXHTRW5ITVJ?
T84	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPaTWM2OD1\|OD63OFA6KM7:TR?=	M1zC[nNCVkeHUh?=
ETK-1	M4XROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HaUmlEPTB;M{muNFIzKM7:TR?=	MlfFV2FPT0WU
COLO-800	MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITvZ\|lKSzVyPUO5MlM5PjhizszN	MXTTRW5ITVJ?
CAL-12T	NYThUJU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHXTWM2OD1\|OT61NlgyKM7:TR?=	MlW1V2FPT0WU
ACN	NHzsVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4[0OmlEPTB;NECuOFkyOSEQvF2=	M4S4WnNCVkeHUh?=
SJSA-1	Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PDRWlEPTB;NEGuNVU6PiEQvF2=	MoP2V2FPT0WU
PSN1	M3nlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LM[WlEPTB;NEGuNVc1QSEQvF2=	MmLUV2FPT0WU
D-566MG	MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTRzLkKwPFYh\|ryP	NF7RXYpUSU6JRWK=
EGI-1	NVe5SpQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7ETWM2OD12Mj60Nlgh\|ryP	NILsUmFUSU6JRWK=
A204	NFOwRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moi5TWM2OD12Mj62N\|g5KM7:TR?=	NVu0U2ZZW0GQR1XS
Saos-2	NV7mPYpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3hZ2c2UUN3ME20Nk45OzZ7IN88US=>	MlrNV2FPT0WU
SNU-C2B	M2XybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGD6Om1KSzVyPUSzMlY5PzhizszN	NYPmTmd6W0GQR1XS
HLE	NU\qOZlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4ThT2lEPTB;NESuNFg2PiEQvF2=	NGXm[nNUSU6JRWK=
SW1463	NVj2WohxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmS4TWM2OD12ND65PVcyKM7:TR?=	MUjTRW5ITVJ?
DSH1	MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPvTWM2OD12NT6wNFM{KM7:TR?=	M4\WfHNCVkeHUh?=
MCF7	NX;CeVN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzPTWM2OD12NT61NFUyKM7:TR?=	MVvTRW5ITVJ?
K5	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUL4bXpwUUN3ME20OU46PDB3IN88US=>	NEHaRZNUSU6JRWK=
NCI-H358	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3f2dGlEPTB;NEeuNlE2KM7:TR?=	NYjPUlRCW0GQR1XS
NCI-H2030	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{[4UWlEPTB;NEeuNlM4PCEQvF2=	MojZV2FPT0WU
SW948	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTR5LkS2OEDPxE1?	Mm[4V2FPT0WU
BALL-1	M16wfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlL1TWM2OD12Nz62NVY5KM7:TR?=	M2i3e3NCVkeHUh?=
TE-9	Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLIRpRKSzVyPUS3Mlk2QDFizszN	NXT2ephlW0GQR1XS
SK-N-FI	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXlRWVwUUN3ME20PE4xOzV6IN88US=>	MUPTRW5ITVJ?
KALS-1	MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnqfWNKSzVyPUS4MlEzQDlizszN	NEj1N2dUSU6JRWK=
HO-1-N-1	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnoO5BmUUN3ME20PE44PDR3IN88US=>	MYfTRW5ITVJ?
NCI-H2452	Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXZOWFKSzVyPUS5MlEyPTJizszN	MljTV2FPT0WU
OC-314	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTR7Lk[4N\|Qh\|ryP	NGPUPWJUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

In vivo

When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. ^[2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. ^[2]

Protocol

Kinase Assay: ^[1]	+ Expand Affinity determination: Binding affinities (K_i or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research: ^[1]	+ Expand Cell lines: SCLC cell lines Concentrations: 0-1 μM Incubation Time: 48 hours Method: Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO₂. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 ⁴) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG Dosages: 100 mg/kg/d Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Navitoclax (ABT-263) SDF

Molecular Weight	974.61
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
CAS No.	923564-51-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03366103	Recruiting	Metastatic Malignant Solid Neoplasm\|Recurrent Malignant Solid Neoplasm\|Recurrent Small Cell Lung Carcinoma\|Stage III Small Cell Lung Carcinoma AJCC v7\|Stage IIIA Small Cell Lung Carcinoma AJCC v7\|Stage IIIB Small Cell Lung Carcinoma AJCC v7\|Stage IV Lung Small Cell Carcinoma AJCC v7\|Unresectable Solid Neoplasm	National Cancer Institute (NCI)	November 29 2017	Phase 1\|Phase 2
NCT03181126	Recruiting	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT03366103	Recruiting	Metastatic Malignant Solid Neoplasm\|Recurrent Malignant Solid Neoplasm\|Recurrent Small Cell Lung Carcinoma\|Stage III Small Cell Lung Carcinoma AJCC v7\|Stage IIIA Small Cell Lung Carcinoma AJCC v7\|Stage IIIB Small Cell Lung Carcinoma AJCC v7\|Stage IV Lung Small Cell Carcinoma AJCC v7\|Unresectable Solid Neoplasm	National Cancer Institute (NCI)	November 29 2017	Phase 1\|Phase 2
NCT03181126	Recruiting	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT03222609	Recruiting	Myelofibrosis (MF)	AbbVie	October 31 2017	Phase 2
NCT03222609	Recruiting	Myelofibrosis (MF)	AbbVie	October 31 2017	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
Answer:
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
Question 2:
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
Answer:
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products4

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)

Cited by 44 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Navitoclax (ABT-263) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)

Cited by 44 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Navitoclax (ABT-263) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)